Up to one in six people in eight industrialised nations could be suffering from chronic kidney disease (CKD) by 2032, with dire consequences for “patients, [the] planet, a
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS
Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabete
AstraZeneca has decided to abandon two phase 3 trials of its drug to reduce high levels of potassium in the blood (hyperkalaemia) – Lokelma – in patients with kidney disea
Combination regimens based on SGLT2 inhibitors and two drugs with different mechanisms of action have shown activity in patients with chronic kidney disease (CKD), raising
Bayer has launched a digital patient support package in England designed to help people with type 2 diabetes look after the health of their kidneys and avoid progression t
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl